Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice

Abstract

The review presents an analysis of studies on the role of armolipid in the primary prevention of cardiovascular diseases. Armolipid is the nutraceutical that combines the lipid-lowering components of red yeast rice (monocalin K, policosanol) and antioxidants (coenzyme Q, astaxanthin and folic acid). The multifactorial evolution of atherosclerotic plaque with dyslipidemia, inflammation and genetic markers and practicability of primary prevention is shown. The presented data demonstrated that the intake of nutraceuticals is well tolerated. It also reduces the levels of total cholesterol, low-density lipoprotein cholesterol and inflammatory markers and improves vascular endothelial function. Nutraceuticals with lipid-lowering effects can be used as an alternative method of primary prevention in people with low and borderline cardiovascular risk before statin therapy, with poor adherence to statin therapy, as well as with statin intolerance or side effects.

Keywords

• dyslipidemia
• primary prevention
• nutraceuticals
• red yeast rice
• armolipid